Big Idea

LiMM Therapeutics is a biopharmaceutical company harnessing the molecular crosstalk between neuronal and innate lymphoid cells (ILCs) within peripheral tissues. By decoding the language of the neuro-immune crosstalk, we are developing first-in-class therapeutic products – NRILs: neuronal reprogrammers of innate lymphocytes – to preserve health and treat inflammatory and metabolic diseases and cancer. We are bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.


David Braga Malta – Founder; Henrique Veiga-Fernandes – Founder

Portugal Ventures’ Investment Manager

Patrícia Costa